Business
/C O R R E C T I O N -- Enliven Therapeutics, Inc./
In the news release, Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update, issued 12-Nov-2025 by Enliven Therapeutics,
About this update from Enliven Therapeutics, Inc.
[{"type":"text","content":"In the news release, Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update, issued 12-Nov-2025 by Enliven Therapeutics, Inc., the Company clarified details surrounding the status of the Phase 1b portion of the ENABLE clinical trial of ELVN-001 in CML.\n Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update\n \n Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML\n \n \n Remains on track to initiate Phase 3 pivotal trial of ELVN-001 in 2026\n \n \n Strong balance sheet with $478 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029\n \n \n BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the third quarter ended September 30, 2025, and provided a business update, including highlights of pipeline progress.\n \"We continue to make great progress advancing the ENABLE Phase 1 trial of ELVN-001 in people living with CML. I'm pleased to report that during the quarter, we completed enrollment of the randomized Phase 1b portion of the ENABLE trial and achieved key readiness milestones across multiple geographies, positioning us to rapidly launch our Phase 3 trial globally next year,\" said Sam Kintz, Co-Founder and Chief Executive Officer of Enliven. \"Since we announced our positive, updated ENABLE data in June, we have had oral presentations at multiple medical meetings, which is a testament to the strength of the data and the potential for ELVN-001 as a selective active-site inhibitor. Additionally, we are pleased that the CML community continues to validate our work and enthusiastically supports ELVN-001 as we move through clinical trials. We remain focused on clinical execution as we look to initiate our Phase 3 pivotal trial in 2026.\"\n \n Pipeline Updates\n \n \n ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML).\n \n \n Completed enrollment of the randomized Phase 1b co...